New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
10:00 EDTXRX, MOS, MNK, IDIX, ANN, VFC, DEI, WCG, TOL, MELI, KBH, CSCO, COP, VNO, LULU, SRPT, MANU, IDTI, BCRX, ARE, HBNCOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Ann Inc. (ANN) downgraded to Neutral from Buy at Janney Capital... BioCryst (BCRX) downgraded to Market Perform from Outperform at Wells Fargo... Cisco (CSCO) downgraded to Underweight from Neutral at JPMorgan... First Niagara (FNFG) downgraded to Hold from Buy at Jefferies... Idenix (IDIX) downgraded to Underperform from Market Perform at JMP Securities... Integrated Device (IDTI) downgraded to Underweight from Equal Weight at Barclays.... KB Home (KBH) downgraded to Underweight from Equal Weight at Barclays... Mallinckrodt (MNK) downgraded to Sell from Neutral at UBS... Manchester United (MANU) downgraded to Hold from Buy at Deutsche Bank... MercadoLibre (MELI) downgraded to Underperform from Neutral at BofA/Merrill... Mosaic (MOS) downgraded to Equal Weight from Overweight at Barclays... Sarepta (SRPT) downgraded to Market Perform from Outperform at JMP Securities... Toll Brothers (TOL) downgraded to Equal Weight from Overweight at Barclays... Xerox (XRX) downgraded to Market Perform from Outperform at BMO Capital... lululemon (LULU) downgraded to Neutral from Buy at Janney Capital... WellCare (WCG) downgraded to Sell from Neutral at Monness Crespi... Horizon Bancorp (HBNC) downgraded to Market Perform from Outperform at Fig Partners... Vornado (VNO) downgraded to Cautious from Neutral at ISI Group... Douglas Emmett (DEI) downgraded to Cautious from Neutral at ISI Group... Alexandria Real Estate (ARE) downgraded to Neutral from Buy at ISI Group... First Niagara (FNFG) downgraded to Underperform from Neutral at Macquarie... ConocoPhillips (COP) downgraded to Neutral from Buy at Guggenheim... VF Corp. (VFC) downgraded to Market Perform from Outperform at Cowen.
News For ANN;BCRX;CSCO;IDIX;IDTI;KBH;MNK;MANU;MELI;MOS;SRPT;TOL;XRX;LULU;WCG;HBNC;VNO;DEI;ARE;COP;VFC From The Last 14 Days
Check below for free stories on ANN;BCRX;CSCO;IDIX;IDTI;KBH;MNK;MANU;MELI;MOS;SRPT;TOL;XRX;LULU;WCG;HBNC;VNO;DEI;ARE;COP;VFC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 7, 2014
19:13 EDTWCGCMS issues 2015 rate announcement for Medicare Advantage and Part D programs
Subscribe for More Information
16:28 EDTIDIX, MNKOn The Fly: Closing Wrap
Subscribe for More Information
13:31 EDTIDIXIdenix risk/reward remains favorable, says UBS
UBS said Idenix's IDX21437 update this morning supports its favorable risk/reward thesis. Shares are Buy rated with an $11 price target.
13:10 EDTLULUlululemon weekly volatility elevated into Analyst Day
Subscribe for More Information
12:15 EDTMNKOn The Fly: Midday Wrap
Subscribe for More Information
11:11 EDTSRPTSarepta said to cancel appearance at Needham conference
Sarepta cancelled its appearance at Needham's conference tomorrow due to "other obligations," a re-tweet by The Street's Adam Feuerstein says, citing a confirmation from the company. Shares of Sarepta moved up 23c to $23.37 following circulation of the tweet.
10:40 EDTMNKShort-seller target Questcor spikes after deal to be bought by Mallinckrodt
Questcor (QCOR) shares are sharply higher this morning after the company agreed to be bought by Mallinckrodt (MNK) in a transaction valued at approximately $5.6B. WHAT'S NEW: Questcor, a biopharmaceutical company whose primary drug, H.P. Acthar Gel, is approved by the FDA for the treatment of 19 indications, will be acquired by Mallinckrodt for about $5.6B, made up of $30.00 per share in cash and 0.897 Mallinckrodt shares for each Questcor share they own. The total consideration equated to approximately $86.10 per Questcor share based on the closing price of Mallinckrodt shares on April 4. After the deal closes, Mallinckrodt shareholders will own approximately 50.5% and former Questcor shareholders will own approximately 49.5% of the combined company's stock. The deal is expected to immediately add to Mallinckrodt's fiscal 2014 adjusted earnings per share and significantly add to fiscal 2015 adjusted EPS. The transaction is targeted to close in the third quarter. On the companies' conference call discussing the merger, Questcor said it believes that its first quarter sales will be "somewhat lower" than the fourth quarter of 2013, but also "substantially higher" than last year's first quarter; the consensus estimate for Q1 revenue is $242.08M. Questcor also said that it sees a "favorable" tax structure and operating cash flow, as well as immediate value for shareholders. Mallinckrodt said sees about a 10% decline in the tax rate with the Questcor deal and believes it will realize immediate tax benefits. Mallinckrodt added that its focus will be on deleveraging in the coming months to allow for strategic acquisitions. WHAT'S NOTABLE: Of the 19 indications approved for Acthar, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions. Questcor has been a frequent target of the short-selling blog Citron Research in the past. As recently as March 14, Citron Research claimed Questcor was "deceiving" the FDA and investors, alleging H.P. Acthar Gel's active ingredient is less than 20% of the label specification. PRICE ACTION: Questcor is trading up $11.48, or 16.91%, to $79.35 in mid-morning trading. Meanwhile, Mallinckrodt is down $1.70, or 2.72%, to $60.82.
10:00 EDTANNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:41 EDTANNAnn Inc. management to meet with JPMorgan
Subscribe for More Information
09:10 EDTMNKOn The Fly: Pre-market Movers
HIGHER: Questcor (QCOR), up 27% after agreeing to be bought by Mallinckrodt (MNK) for cash, stock valued at $86.10 per Questcor share... Agios Pharmaceuticals (AGIO), up 25% after program shows "promising clinical activity" for advanced blood cancers, shares upgraded at JPMorgan... Vocus (VOCS), up 47% after agreeing to be acquired by GTCR for $446.5M, or $18.00 per share... Pandora (P), up 1.3% following upgrade at Wedbush. LOWER: MannKind (MNKD), down 13% after announcing FDA extension of PDUFA date for Afrezza... American Eagle (AEO), down 2.2% following downgrade at Cowen... Pfizer (PFE), down 2.8% after announcing data for palbociclib in metastatic breast cancer... Mattel (MAT), down 3% following downgrade at BMO Capital... WWE (WWE), down 1.2% after cautious mention in Barron's, company announcing WrestleMania 30 grossed $10.9M.
09:00 EDTMNKMallinckrodt rises 6.1%
Mallinckrodt is up 6.1%, or $3.83, to $66.35
08:15 EDTCSCOCisco, Sony collaborate on live delivery of full-frame rate 4K 60P content
Subscribe for More Information
07:38 EDTLULUlululemon reiterated as a Buy ahead of Analyst Day at Topeka
Topeka expects lululemon's April 17 Analyst Day to be a "very positive" event and reiterates its Buy rating and $70 price target ahead of the event. The analyst said the new CEO is on a marketing offensive as the store base expands worldwide and new heads of merchandising and sourcing are working to maintain a high quality, innovative product.
07:16 EDTMNKMallinckrodt and Questcor hold a joint conference call
Subscribe for More Information
07:15 EDTIDIXIdenix announces promising clinical data, continued progress in HCV programs
Idenix Pharmaceuticals announced continued progress of the Company's program to develop nucleotide prodrug inhibitors for the treatment of hepatitis C virus, or HCV, infection. Idenix is reporting potent antiviral activity of mean maximum 4.2-4.3 log10 IU/mL reductions for patients infected with HCV genotype 1, 2 or 3 receiving 300 mg once daily of IDX21437 in the seven-day proof-of-concept portion of a phase I/II clinical trial. Based on this progress, the Company's goal is to initiate a combination clinical trial of IDX21437 and samatasvir, a pan-genotypic NS5A inhibitor, in mid-2014. In addition, Idenix has selected a follow-on uridine-based nucleotide prodrug, IDX21459, from its ongoing nucleotide discovery program and initiated enrollment for the healthy volunteer portion of a phase I clinical trial. In January, Idenix initiated the seven-day proof-of-concept portion of a phase I/II clinical trial for IDX21437. The trial completed enrollment of 44 treatment-nave, genotype, or GT, 1, 2 or 3 HCV-infected patients. Patients were randomized to receive once-daily doses of placebo, 50 mg, 150 mg, or 300 mg of IDX21437 for seven days. In April 2014, Idenix initiated enrollment for the healthy volunteer portion of a phase I clinical trial of IDX21459 in Europe. This portion of the study is expected to enroll approximately 50 healthy volunteers and will evaluate once-daily doses of IDX21459 ranging from 10 mg 300 mg. The proof-of-concept portion of the study is expected to enroll a total of 40 treatment-nave, genotype 1 HCV-infected patients who will receive once-daily doses of placebo, 50 - 300 mg of IDX21459 for seven days. IDX21459 has shown a favorable preclinical profile including potent, pan-genotypic activity and favorable safety with respect to cardiac, mitochondrial and genotoxicity assessments.
07:12 EDTANNAnn Inc. downgraded at Oppenheimer
As noted earlier, Oppenheimer downgraded Ann to Perform from Outperform. The firm downgraded the stock based on valuation, lack of catalysts, and challenging comps after Q1. Target $40.
07:08 EDTMNKQuestcor to be bought by Mallinckrodt for cash, stock valued at $86.10 per share
Subscribe for More Information
07:04 EDTMNKQuestcor acquired by Mallinckrodt for $5.6B
Subscribe for More Information
06:59 EDTANNAnn Inc.price target raised to $48 from $40 at UBS
Subscribe for More Information
06:29 EDTANNAnn Inc. downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use